InsightRx — Healthcare Market Research Firm India
Sector Intelligence

Private Equity in Indian Healthcare 2026: Deal Trends, Valuations, and What Exits Actually Look Like

Private equity and venture capital deploy roughly US$ 2–3 billion or more annually into Indian healthcare. The composition has shifted decisively: hospitals absorb the largest share, pharma services (CDMO/CRO) is the strongest thematic bid, and digital health has fallen down the funding order. Deployment is not the achievement — exits at underwritten returns are.

July 202617 pagesFree download

Free Report

Private Equity in Indian Healthcare 2026: Deal Trends, Valuations, and What Exits Actually Look Like

July 202617 pages · PDFPrimary research by InsightRx

No spam. Instant download.

Key Findings

  • 1

    PE/VC deploy US$ 2–3 billion+ annually into Indian healthcare — ~US$ 500–600 million per quarter

  • 2

    Hospitals and single-specialty chains absorb the largest share of capital

  • 3

    Pharma services (CDMO/CRO) is the strongest thematic bid, driven by China+1 diversification

  • 4

    Digital health funding has compressed sharply from its 2021 peak

  • 5

    Quality hospital assets now transact at high-teens EV/EBITDA

  • 6

    Secondary sales between PE funds increasingly dominate exit routes — recycling risk rather than realising the thesis

Where the Capital Goes

Hospitals (the anchor theme), pharma services (the momentum theme), diagnostics (steady, cash-generative), and digital health (the reckoning — billions absorbed in 2020–22, funding since compressed sharply).

The Valuation Problem, Stated Plainly

Healthcare's defensive growth story is precisely why it is expensive. Quality hospital platforms have transacted at high-teens EV/EBITDA and above. At these entry points, operational value creation must do all the work.

The Exit Record: Read It Before Repeating the Thesis

Marquee exits are concentrated in a small number of assets. Secondary sales between financial sponsors increasingly dominate exit routes. The digital-health vintage of 2020–22 will, in aggregate, return well below cost.

What LPs and Promoters Should Each Take from This

For investors: the durable playbook remains buy-and-build below platform multiples. For promoters: this is a seller's market for quality assets — preparation routinely moves outcomes by turns of EBITDA.

Free Download

Get the full 17-page report

Primary research, data-backed findings, and strategic recommendations — all in one PDF. Free to download.

Frequently Asked Questions

How much private equity is invested in Indian healthcare?

Roughly US$ 2–3 billion or more annually across PE and VC, with recent quarters running at ~US$ 500–600 million.

What are hospital valuation multiples in India?

Quality hospital platforms have transacted at high-teens EV/EBITDA multiples and above, broadly in line with listed hospital chains.

Is now a good time to sell a hospital business in India?

Capital supply for quality healthcare assets is strong, making it a favourable window for prepared sellers — those with clean financials, clear payer mix, and locked-in clinical talent typically achieve materially better outcomes.

Custom Research

Need custom research on this market?

Our published reports cover broad themes. For research specific to your geography, therapy area, or competitive situation, talk to InsightRx.